Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar

(MedPage Today) — The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer.
FDA granted the targeted agent an…